Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - Takeaways - MDSpire

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • By

  • Julio Rosenstock

  • Ildiko Lingvay

  • Donna Ryan

  • Ania M. Jastreboff

  • Robert Kushner

  • Andres Acosta

  • Thomas C. Blevins

  • Melissa Choi

  • Faith L. Holmes

  • Timothy Smith

  • Lisa Connery

  • Yao Li

  • Mike Ke Liu

  • Aline Barth

  • Jamie Butcher

  • Antonio Civitarese

  • Huibin Yue

  • Blai Coll

  • June 5, 2026

  • 0 min

Share

  • 1

    Aleniglipron is a small-molecule GLP-1 receptor agonist developed for obesity treatment, offering oral administration and improved accessibility.

  • 2

    The ACCESS phase-2b study evaluated aleniglipron's efficacy, safety, and tolerability over 36 weeks in adults with obesity or overweight.

  • 3

    Participants receiving aleniglipron showed significant weight loss compared to placebo, with reductions of up to 12.1% in body weight at 120 mg.

  • 4

    Secondary outcomes indicated that 86% of participants on 120 mg aleniglipron achieved ≥5% weight loss, compared to 23% in the placebo group.

  • 5

    Common treatment-emergent adverse events included gastrointestinal issues, with most participants tolerating the titration schedule well.

Original Source(s)

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • by Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll

  • June 5, 2026

Related Content

Affordable GLP-1? When Digital Platforms Meet Policy Reform

Editorial: Cardiovascular Anthropometry For Large Scale Population Studies Volume II

Side Effects: The Body Keeps Score

Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.